Search

Your search keyword '"Liu, Enli"' showing total 447 results
Start Over Author "Liu, Enli"
447 results on '"Liu, Enli"'

2. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

Author

Marin, David, Li, Ye, Basar, Rafet, Rafei, Hind, Daher, May, Dou, Jinzhuang, Mohanty, Vakul, Dede, Merve, Nieto, Yago, Uprety, Nadima, Acharya, Sunil, Liu, Enli, Wilson, Jeffrey, Banerjee, Pinaki, Macapinlac, Homer A., Ganesh, Christina, Thall, Peter F., Bassett, Roland, Ammari, Mariam, Rao, Sheetal, Cao, Kai, Shanley, Mayra, Kaplan, Mecit, Hosing, Chitra, Kebriaei, Partow, Nastoupil, Loretta J., Flowers, Christopher R., Moseley, Sadie Mae, Lin, Paul, Ang, Sonny, Popat, Uday R., Qazilbash, Muzaffar H., Champlin, Richard E., Chen, Ken, Shpall, Elizabeth J., and Rezvani, Katayoun

Published
2024
Full Text
View/download PDF

5. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD

Author

Shanley, Mayra, Daher, May, Dou, Jinzhuang, Li, Sufang, Basar, Rafet, Rafei, Hind, Dede, Merve, Gumin, Joy, Pantaleόn Garcίa, Jezreel, Nunez Cortes, Ana Karen, He, Shan, Jones, Corry M., Acharya, Sunil, Fowlkes, Natalie W., Xiong, Donghai, Singh, Sanjay, Shaim, Hila, Hicks, Samantha Claire, Liu, Bin, Jain, Abhinav, Zaman, Mohammad Fayyad, Miao, Qi, Li, Ye, Uprety, Nadima, Liu, Enli, Muniz-Feliciano, Luis, Deyter, Gary M., Mohanty, Vakul, Zhang, Patrick, Evans, Scott E., Shpall, Elizabeth J., Lang, Frederick F., Chen, Ken, and Rezvani, Katayoun

Published
2024
Full Text
View/download PDF

6. Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape

Author

Li, Ye, Basar, Rafet, Wang, Guohui, Liu, Enli, Moyes, Judy S., Li, Li, Kerbauy, Lucila N., Uprety, Nadima, Fathi, Mohsen, Rezvan, Ali, Banerjee, Pinaki P., Muniz-Feliciano, Luis, Laskowski, Tamara J., Ensley, Emily, Daher, May, Shanley, Mayra, Mendt, Mayela, Acharya, Sunil, Liu, Bin, Biederstädt, Alexander, Rafei, Hind, Guo, Xingliang, Melo Garcia, Luciana, Lin, Paul, Ang, Sonny, Marin, David, Chen, Ken, Bover, Laura, Champlin, Richard E., Varadarajan, Navin, Shpall, Elizabeth J., and Rezvani, Katayoun

Published
2024
Full Text
View/download PDF

8. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape

Author

Li, Ye, Basar, Rafet, Wang, Guohui, Liu, Enli, Moyes, Judy S., Li, Li, Kerbauy, Lucila N., Uprety, Nadima, Fathi, Mohsen, Rezvan, Ali, Banerjee, Pinaki P., Muniz-Feliciano, Luis, Laskowski, Tamara J., Ensley, Emily, Daher, May, Shanley, Mayra, Mendt, Mayela, Acharya, Sunil, Liu, Bin, Biederstädt, Alexander, Rafei, Hind, Guo, Xingliang, Melo Garcia, Luciana, Lin, Paul, Ang, Sonny, Marin, David, Chen, Ken, Bover, Laura, Champlin, Richard E., Varadarajan, Navin, Shpall, Elizabeth J., and Rezvani, Katayoun

Published
2022
Full Text
View/download PDF

12. Phase I study of cord blood‐derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma

Author

Shah, Nina, Li, Li, McCarty, Jessica, Kaur, Indreshpal, Yvon, Eric, Shaim, Hila, Muftuoglu, Muharrem, Liu, Enli, Orlowski, Robert Z, Cooper, Laurence, Lee, Dean, Parmar, Simrit, Cao, Kai, Sobieiski, Catherine, Saliba, Rima, Hosing, Chitra, Ahmed, Sairah, Nieto, Yago, Bashir, Qaiser, Patel, Krina, Bollard, Catherine, Qazilbash, Muzaffar, Champlin, Richard, Rezvani, Katy, and Shpall, Elizabeth J

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Stem Cell Research, Stem Cell Research - Umbilical Cord Blood/ Placenta - Human, Rare Diseases, Clinical Research, Regenerative Medicine, Hematology, Transplantation, Immunotherapy, Minority Health, Stem Cell Research - Umbilical Cord Blood/ Placenta, Stem Cell Research - Nonembryonic - Human, Cancer, 2.1 Biological and endogenous factors, Adoptive Transfer, Aged, Antineoplastic Combined Chemotherapy Protocols, Cell Separation, Combined Modality Therapy, Female, Fetal Blood, Flow Cytometry, Graft Survival, Hematopoietic Stem Cell Transplantation, Humans, Killer Cells, Natural, Lenalidomide, Male, Melphalan, Middle Aged, Multiple Myeloma, Thalidomide, Treatment Outcome, myeloma, natural killer, cord blood, exvivo expansion, autologous transplant, ex vivo expansion, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

Multiple myeloma (MM) is a disease with known immune dysregulation. Natural killer (NK) cells have shown preclinical activity in MM. We conducted a first-in-human study of umbilical cord blood-derived (CB) NK cells for MM patients undergoing high dose chemotherapy and autologous haematopoietic stem cell transplantation (auto-HCT). Patients received lenalidomide (10 mg) on days -8 to -2, melphalan 200 mg/m2 on day -7, CB-NK cells on day -5 and auto-HCT on day 0. Twelve patients were enrolled, three on each of four CB-NK cell dose levels: 5 × 106 , 1 × 107 , 5 × 107 and 1 × 108 CB-NK cells/kg. Ten patients had either high-risk chromosomal changes or a history of relapsed/progressed disease. There were no infusional toxicities and no graft-versus-host disease. One patient failed to engraft due to poor autologous graft quality and was rescued with a back-up autologous graft. Overall, 10 patients achieved at least a very good partial response as their best response, including eight with near complete response or better. With a median follow-up of 21 months, four patients have progressed or relapsed, two of whom have died. CB-NK cells were detected in vivo in six patients, with an activated phenotype (NKG2D+ /NKp30+ ). These data warrant further development of this novel cellular therapy.

Published
2017

13. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells

Author

Daher, May, Basar, Rafet, Gokdemir, Elif, Baran, Natalia, Uprety, Nadima, Nunez Cortes, Ana Karen, Mendt, Mayela, Kerbauy, Lucila Nassif, Banerjee, Pinaki P., Shanley, Mayra, Imahashi, Nobuhiko, Li, Li, Lim, Francesca Lorraine Wei Inng, Fathi, Mohsen, Rezvan, Ali, Mohanty, Vakul, Shen, Yifei, Shaim, Hila, Lu, Junjun, Ozcan, Gonca, Ensley, Emily, Kaplan, Mecit, Nandivada, Vandana, Bdiwi, Mustafa, Acharya, Sunil, Xi, Yuanxin, Wan, Xinhai, Mak, Duncan, Liu, Enli, Jiang, Xin Ru, Ang, Sonny, Muniz-Feliciano, Luis, Li, Ye, Wang, Jing, Kordasti, Shahram, Petrov, Nedyalko, Varadarajan, Navin, Marin, David, Brunetti, Lorenzo, Skinner, Richard J., Lyu, Shangrong, Silva, Leiser, Turk, Rolf, Schubert, Mollie S., Rettig, Garrett R., McNeill, Matthew S., Kurgan, Gavin, Behlke, Mark A., Li, Heng, Fowlkes, Natalie W., Chen, Ken, Konopleva, Marina, Champlin, Richard E., Shpall, Elizabeth J., and Rezvani, Katayoun

Published
2021
Full Text
View/download PDF

15. Large-scale GMP-compliant CRISPR-Cas9–mediated deletion of the glucocorticoid receptor in multivirus-specific T cells

Author

Basar, Rafet, Daher, May, Uprety, Nadima, Gokdemir, Elif, Alsuliman, Abdullah, Ensley, Emily, Ozcan, Gonca, Mendt, Mayela, Hernandez Sanabria, Mayra, Kerbauy, Lucila Nassif, Nunez Cortes, Ana Karen, Li, Li, Banerjee, Pinaki P., Muniz-Feliciano, Luis, Acharya, Sunil, Fowlkes, Natalie W., Lu, Junjun, Li, Sufang, Mielke, Stephan, Kaplan, Mecit, Nandivada, Vandana, Bdaiwi, Mustafa, Kontoyiannis, Alexander D., Li, Ye, Liu, Enli, Ang, Sonny, Marin, David, Brunetti, Lorenzo, Gundry, Michael C., Turk, Rolf, Schubert, Mollie S., Rettig, Garrett R., McNeill, Matthew S., Kurgan, Gavin, Behlke, Mark A., Champlin, Richard, Shpall, Elizabeth J., and Rezvani, Katayoun

Published
2020
Full Text
View/download PDF

20. A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML

Author

Alsuliman, Abdullah, Muftuoglu, Muharrem, Khoder, Ahmad, Ahn, Yong-Oon, Basar, Rafet, Verneris, Michael R., Muranski, Pawel, Barrett, A.John, Liu, Enli, Li, Li, Stringaris, Kate, Armstrong-James, Darius, Shaim, Hila, Kondo, Kayo, Imahashi, Nobuhiko, Andersson, Borje, Marin, David, Champlin, Richard E., Shpall, Elizabeth J., and Rezvani, Katayoun

Published
2017
Full Text
View/download PDF

21. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering

Author

Li, Li, primary, Mohanty, Vakul, additional, Dou, Jinzhuang, additional, Huang, Yuefan, additional, Banerjee, Pinaki P., additional, Miao, Qi, additional, Lohr, Jens G., additional, Vijaykumar, Tushara, additional, Frede, Julia, additional, Knoechel, Birgit, additional, Muniz-Feliciano, Luis, additional, Laskowski, Tamara J., additional, Liang, Shaoheng, additional, Moyes, Judy S., additional, Nandivada, Vandana, additional, Basar, Rafet, additional, Kaplan, Mecit, additional, Daher, May, additional, Liu, Enli, additional, Li, Ye, additional, Acharya, Sunil, additional, Lin, Paul, additional, Shanley, Mayra, additional, Rafei, Hind, additional, Marin, David, additional, Mielke, Stephan, additional, Champlin, Richard E., additional, Shpall, Elizabeth J., additional, Chen, Ken, additional, and Rezvani, Katayoun, additional

Published
2023
Full Text
View/download PDF

24. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation

Author

Sarvaria, Anushruti, Basar, Rafet, Mehta, Rohtesh S., Shaim, Hila, Muftuoglu, Muharrem, Khoder, Ahmad, Sekine, Takuye, Gokdemir, Elif, Kondo, Kayo, Marin, David, Daher, May, Alousi, Amin M., Alsuliman, Abdullah, Liu, Enli, Oran, Betul, Olson, Amanda, Jones, Roy B., Popat, Uday, Hosing, Chitra, Champlin, Richard, Shpall, Elizabeth J., and Rezvani, Katayoun

Published
2016
Full Text
View/download PDF

25. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation

Author

Sekine, Takuya, Marin, David, Cao, Kai, Li, Li, Mehta, Pramod, Shaim, Hila, Sobieski, Catherine, Jones, Roy, Oran, Betul, Hosing, Chitra, Rondon, Gabriela, Alsuliman, Abdullah, Paust, Silke, Andersson, Borje, Popat, Uday, Kebriaei, Partow, Muftuoglu, Muharrem, Basar, Rafet, Kondo, Kayo, Nieto, Yago, Shah, Nina, Olson, Amanda, Alousi, Amin, Liu, Enli, Sarvaria, Anushruti, Parmar, Simrit, Armstrong-James, Darius, Imahashi, Nobuhiko, Molldrem, Jeffrey, Champlin, Richard, Shpall, Elizabeth J., and Rezvani, Katayoun

Published
2016
Full Text
View/download PDF

28. Supplementary Figure S4 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

Author

Kerbauy, Lucila N., primary, Marin, Nancy D., primary, Kaplan, Mecit, primary, Banerjee, Pinaki P., primary, Berrien-Elliott, Melissa M., primary, Becker-Hapak, Michelle, primary, Basar, Rafet, primary, Foster, Mark, primary, Garcia Melo, Luciana, primary, Neal, Carly C., primary, McClain, Ethan, primary, Daher, May, primary, Nunez Cortes, Ana Karen, primary, Desai, Sweta, primary, Inng Lim, Francesca Wei, primary, Mendt, Mayela Carolina, primary, Schappe, Timothy, primary, Li, Li, primary, Shaim, Hila, primary, Shanley, Mayra, primary, Ensley, Emily L., primary, Uprety, Nadima, primary, Wong, Pamela, primary, Liu, Enli, primary, Ang, Sonny O., primary, Cai, Rong, primary, Nandivada, Vandana, primary, Mohanty, Vakul, primary, Miao, Qi, primary, Shen, Yifei, primary, Baran, Natalia, primary, Fowlkes, Natalie W., primary, Chen, Ken, primary, Muniz-Feliciano, Luis, primary, Champlin, Richard E., primary, Nieto, Yago L., primary, Koch, Joachim, primary, Treder, Martin, primary, Fischer, Wolfgang, primary, Okamoto, Oswaldo Keith, primary, Shpall, Elizabeth J., primary, Fehniger, Todd A., primary, and Rezvani, Katayoun, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table S2 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

Author

Kerbauy, Lucila N., primary, Marin, Nancy D., primary, Kaplan, Mecit, primary, Banerjee, Pinaki P., primary, Berrien-Elliott, Melissa M., primary, Becker-Hapak, Michelle, primary, Basar, Rafet, primary, Foster, Mark, primary, Garcia Melo, Luciana, primary, Neal, Carly C., primary, McClain, Ethan, primary, Daher, May, primary, Nunez Cortes, Ana Karen, primary, Desai, Sweta, primary, Inng Lim, Francesca Wei, primary, Mendt, Mayela Carolina, primary, Schappe, Timothy, primary, Li, Li, primary, Shaim, Hila, primary, Shanley, Mayra, primary, Ensley, Emily L., primary, Uprety, Nadima, primary, Wong, Pamela, primary, Liu, Enli, primary, Ang, Sonny O., primary, Cai, Rong, primary, Nandivada, Vandana, primary, Mohanty, Vakul, primary, Miao, Qi, primary, Shen, Yifei, primary, Baran, Natalia, primary, Fowlkes, Natalie W., primary, Chen, Ken, primary, Muniz-Feliciano, Luis, primary, Champlin, Richard E., primary, Nieto, Yago L., primary, Koch, Joachim, primary, Treder, Martin, primary, Fischer, Wolfgang, primary, Okamoto, Oswaldo Keith, primary, Shpall, Elizabeth J., primary, Fehniger, Todd A., primary, and Rezvani, Katayoun, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Materials and Methods from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

Author

Kerbauy, Lucila N., primary, Marin, Nancy D., primary, Kaplan, Mecit, primary, Banerjee, Pinaki P., primary, Berrien-Elliott, Melissa M., primary, Becker-Hapak, Michelle, primary, Basar, Rafet, primary, Foster, Mark, primary, Garcia Melo, Luciana, primary, Neal, Carly C., primary, McClain, Ethan, primary, Daher, May, primary, Nunez Cortes, Ana Karen, primary, Desai, Sweta, primary, Inng Lim, Francesca Wei, primary, Mendt, Mayela Carolina, primary, Schappe, Timothy, primary, Li, Li, primary, Shaim, Hila, primary, Shanley, Mayra, primary, Ensley, Emily L., primary, Uprety, Nadima, primary, Wong, Pamela, primary, Liu, Enli, primary, Ang, Sonny O., primary, Cai, Rong, primary, Nandivada, Vandana, primary, Mohanty, Vakul, primary, Miao, Qi, primary, Shen, Yifei, primary, Baran, Natalia, primary, Fowlkes, Natalie W., primary, Chen, Ken, primary, Muniz-Feliciano, Luis, primary, Champlin, Richard E., primary, Nieto, Yago L., primary, Koch, Joachim, primary, Treder, Martin, primary, Fischer, Wolfgang, primary, Okamoto, Oswaldo Keith, primary, Shpall, Elizabeth J., primary, Fehniger, Todd A., primary, and Rezvani, Katayoun, primary

Published
2023
Full Text
View/download PDF

35. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD

Author

Khoder, Ahmad, Sarvaria, Anushruti, Alsuliman, Abdullah, Chew, Claude, Sekine, Takuya, Cooper, Nichola, Mielke, Stephan, de Lavallade, Hugues, Muftuoglu, Muharrem, Fernandez Curbelo, Irina, Liu, Enli, Muraro, Paolo A., Alousi, Amin, Stringaris, Kate, Parmar, Simrit, Shah, Nina, Shaim, Hila, Yvon, Eric, Molldrem, Jeffrey, Rouce, Rayne, Champlin, Richard, McNiece, Ian, Mauri, Claudia, Shpall, Elizabeth J., and Rezvani, Katayoun

Published
2014
Full Text
View/download PDF

38. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains

Author

Ramos, Carlos A., Savoldo, Barbara, Torrano, Vicky, Ballard, Brandon, Zhang, Huimin, Dakhova, Olga, Liu, Enli, Carrum, George, Kamble, Rammurti T., Gee, Adrian P., Mei, Zhuyong, Wu, Meng-Fen, Liu, Hao, Grilley, Bambi, Rooney, Cliona M., Brenner, Malcolm K., Heslop, Helen E., and Dotti, Gianpietro

Subjects
Antigen-antibody reactions -- Physiological aspects, T cells -- Physiological aspects, Health care industry
Abstract

BACKGROUND. Treatment of B cell malignancies with adoptive transfer of T cells with a CD19-specific chimeric antigen receptor (CAR) shows remarkable clinical efficacy. However, long-term persistence of T cells targeting CD19, a pan-B cell marker, also depletes normal B cells and causes severe hypogammaglobulinemia. Here, we developed a strategy to target B cell malignancies more selectively by taking advantage of B cell light Ig chain restriction. We generated a CAR that is specific for the κ light chain (κ.CAR) and therefore recognizes κ-restricted cells and spares the normal B cells expressing the nontargeted λ light chain, thus potentially minimizing humoral immunity impairment. METHODS. We conducted a phase 1 clinical trial and treated 16 patients with relapsed or refractory [κ.sup.+] non- Hodgkin lymphoma/chronic lymphocytic leukemia (NHL/CLL) or multiple myeloma (MM) with autologous T cells genetically modified to express κ.CAR (κ.CARTs). Other treatments were discontinued in 11 of the 16 patients at least 4 weeks prior to T cell infusion. Six patients without lymphopenia received 12.5 mg/kg cyclophosphamide 4 days before κ.CART infusion (0.2 x [10.sup.8] to 2 x [10.sup.8] κ.CARTs/[m.sup.2]). No other lymphodepletion was used. RESULTS. κ.CART expansion peaked 1-2 weeks after infusion, and cells remained detectable for more than 6 weeks. Of 9 patients with relapsed NHL or CLL, 2 entered complete remission after 2 and 3 infusions of κ.CARTs, and 1 had a partial response. Of 7 patients with MM, 4 had stable disease lasting 2-17 months. No toxicities attributable to κ.CARTs were observed. CONCLUSION. κ.CART infusion is feasible and safe and can lead to complete clinical responses. TRIAL REGISTRATION. ClinicalTrials.gov NCT00881920. FUNDING. National Cancer Institute (NCI) grants 3P50CA126752 and 5P30CA125123 and Leukemia and Lymphoma Society (LLS) Specialized Centers of Research (SCOR) grant 7018., Introduction Chimeric antigen receptors (CARs) most commonly combine the antigen-recognizing portion of a mAb with the signaling machinery of T cells. When these molecules are genetically grafted into T lymphocytes, [...]

Published
2016
Full Text
View/download PDF

39. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+B cell tumors: a phase 1/2 trial

Author

Marin, David, Li, Ye, Basar, Rafet, Rafei, Hind, Daher, May, Dou, Jinzhuang, Mohanty, Vakul, Dede, Merve, Nieto, Yago, Uprety, Nadima, Acharya, Sunil, Liu, Enli, Wilson, Jeffrey, Banerjee, Pinaki, Macapinlac, Homer A., Ganesh, Christina, Thall, Peter F., Bassett, Roland, Ammari, Mariam, Rao, Sheetal, Cao, Kai, Shanley, Mayra, Kaplan, Mecit, Hosing, Chitra, Kebriaei, Partow, Nastoupil, Loretta J., Flowers, Christopher R., Moseley, Sadie Mae, Lin, Paul, Ang, Sonny, Popat, Uday R., Qazilbash, Muzaffar H., Champlin, Richard E., Chen, Ken, Shpall, Elizabeth J., and Rezvani, Katayoun

Abstract

There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord blood-derived natural killer (NK) cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15) in 37 patients with CD19+B cell malignancies. The primary objectives were safety and efficacy, defined as day 30 overall response (OR). Secondary objectives included day 100 response, progression-free survival, overall survival and CAR19/IL-15 NK cell persistence. No notable toxicities such as cytokine release syndrome, neurotoxicity or graft-versus-host disease were observed. The day 30 and day 100 OR rates were 48.6% for both. The 1-year overall survival and progression-free survival were 68% and 32%, respectively. Patients who achieved OR had higher levels and longer persistence of CAR-NK cells. Receiving CAR-NK cells from a cord blood unit (CBU) with nucleated red blood cells ≤ 8 × 107and a collection-to-cryopreservation time ≤ 24 h was the most significant predictor for superior outcome. NK cells from these optimal CBUs were highly functional and enriched in effector-related genes. In contrast, NK cells from suboptimal CBUs had upregulation of inflammation, hypoxia and cellular stress programs. Finally, using multiple mouse models, we confirmed the superior antitumor activity of CAR/IL-15 NK cells from optimal CBUs in vivo. These findings uncover new features of CAR-NK cell biology and underscore the importance of donor selection for allogeneic cell therapies. ClinicalTrials.gov identifier: NCT03056339.

Published
2024
Full Text
View/download PDF

40. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

Author

Cruz, Conrad Russell Y., Micklethwaite, Kenneth P., Savoldo, Barbara, Ramos, Carlos A., Lam, Sharon, Ku, Stephanie, Diouf, Oumar, Liu, Enli, Barrett, A. John, Ito, Sawa, Shpall, Elizabeth J., Krance, Robert A., Kamble, Rammurti T., Carrum, George, Hosing, Chitra M., Gee, Adrian P., Mei, Zhuyong, Grilley, Bambi J., Heslop, Helen E., Rooney, Cliona M., Brenner, Malcolm K., Bollard, Catherine M., and Dotti, Gianpietro

Published
2013
Full Text
View/download PDF

48. Epigenetic Scarring Leads to Irreversible NK Cell Dysfunction in Myeloid Malignancies

Author

Kumar, Bijender, Singh, Anand, Basar, Rafet, Uprety, Nadima, Li, Ye, Fan, Huihui, Shanley, Mayra, Acharya, Sunil, Mendt, Mayela Carolina, Lin, Paul, Biederstädt, Alexander, Rafei, Hind, Banerjee, Pinaki, Mohanty, Vakul, Shaim, Hila, Dede, Merve, Melo Garcia, Luciana, Kerbauy, Lucila Nassif, Nunez Cortes, Ana K., Miao, Qi, Dou, Jinzhuang, Silva Reyes, Francia, Guo, Xingliang, Kaplan, Mecit, Ang, Sonny, Jiang, Xin Ru, Liu, Enli, Liu, Bin, Champlin, Richard E., Kantarjian, Hagop, Marin, David, Chen, Ken, Abbas, Hussein A, Shpall, Elizabeth J., Rai, Kunal, Rezvani, Katayoun, and Daher, MD, May

Published
2023
Full Text
View/download PDF

49. DAP10 Co-Stimulation Imparts Memory-like Features to CD5 Targeting Cord Blood Derived CAR-NK Cells

Author

Basar, Rafet, Daher, MD, May, Uprety, Nadima, Ensley, Emily, Nunez Cortes, Ana K., Acharya, Sunil, Shrestha, Rejeena, Liu, Bin, Shanley, Mayra, Li, Ye, Silva Reyes, Francia, Dede, Merve, Rafei, Hind, Shaim, Hila, Kaplan, Mecit, Lin, Paul, Banerjee, Pinaki, Mohanty, Vakul, Dou, Jinhuang, Mendt, Mayela Carolina, Miao, Qi, Ammari, Mariam, Liu, Enli, Guo, Xingliang, Kumar, Bijender, Biederstädt, Alexander, Jiang, Xin Ru, Ang, Sonny, Varadarajan, Navin, Champlin, Richard E., Chen, Ken, Marin, David, Shpall, Elizabeth J., and Rezvani, Katayoun

Published
2023
Full Text
View/download PDF

50. NK Cell Dysfunction in CLL Is Mediated through SHP-1 Signaling and Is Associated with Poor Prognosis

Author

Shaim, Hila, Rafei, Hind, Kaplan, Mecit, Basar, Rafet, Daher, MD, May, Shanley, Mayra, Banerjee, Pinaki, Kumar, Bijender, Nunez Cortes, Ana K., Islam, Sanjida, Jiang, Xin Ru, Kerbauy, Lucila Nassif, Lin, Paul, Gokdemir, Elif, Uprety, Nadima, Acharya, Sunil, Mendt, Mayela Carolina, Melo Garcia, Luciana, Biederstädt, Alexander, Liu, Bin, Liu, Enli, Ang, Sonny, Burger, Jan A., Wierda, William G., Ferrajoli, Alessandra, Shpall, Elizabeth J., and Rezvani, Katayoun

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results